Lopez-Lopez Victor, Kuemmerli Christoph, Iniesta Maria, Hiciano-Guillermo Alberto, Cascales-Campos Pedro, Baroja-Mazo Alberto, Antonio-Pons Jose, Sánchez-Esquer Ignacio, Ferreras David, Sánchez-Bueno Francisco, Ramírez Pablo, Robles-Campos Ricardo
Department of General and Digestive Surgery, Virgen de la Arrixaca University Hospital, IMIB-Arrixaca, Murcia, Spain.
Digestive and Endocrine Surgery and Transplantation of Abdominal Organs Research Group, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
Ann Surg. 2024 Aug 23. doi: 10.1097/SLA.0000000000006502.
We analyzed the use of a self-expandable absorbable biliary stent (SEABS) to reduce biliary complications in liver transplant (LT).
Complications related to biliary anastomosis are a still a challenge in LT with a high impact on the patient outcomes and hospital costs.
This non-randomized prospective study was conducted between July 2019 and September 2023 in adult LT patients with duct-to-duct biliary anastomoses. The primary endpoint was to assess early biliary complications at 90 days in LT patients with intraoperative SEABS versus no SEABS. We also compared overall biliary complications, costs and SEABS- adverse effects related.
A total of 158 patients were included, 78 with SEABS and 80 no-SEABS (22 T-tube and 58 no-stent). There were no adverse effects related to SEABS. Early biliary complications (23.8 vs 2.6%, P <0.001) and hospital stay (19 vs 15 days, P= 0.001) were higher in no-SEABS. No-SEABS group required 63 ERCPs and 13 surgeries (including 2 LT) versus 35 ERCPs and 2 surgeries in SEABS group. After PSM between SEABS (n=58) vs no-SEABS (n=58), early biliary complications (40% vs 0%, P<.001) were higher in no-SEABS group. T-tube had more early biliary complications (22.7% vs 5%, P=0.23) compared SEABS high-risk biliary anastomosis. SEABS excess cost per patient was lower compared to T-Tube and no-stent (6.988€ vs 17.992€ vs 36.364€, P=0.036 and P=0.002, respectively).
SEABS during biliary anastomosis in LT is feasible with no adverse effects and avoid the T-tube in high-risk biliary anastomoses. It use has been associated with less early biliary complications, hospital costs and reoperations or interventional treatments for biliary complications resolution.
我们分析了使用自膨胀可吸收胆管支架(SEABS)来减少肝移植(LT)中的胆道并发症。
与胆管吻合相关的并发症在肝移植中仍然是一个挑战,对患者预后和医院成本有很大影响。
这项非随机前瞻性研究于2019年7月至2023年9月在进行胆管对胆管吻合的成年肝移植患者中开展。主要终点是评估术中使用SEABS与未使用SEABS的肝移植患者在90天时的早期胆道并发症。我们还比较了总体胆道并发症、成本以及与SEABS相关的不良反应。
共纳入158例患者,78例使用SEABS,80例未使用SEABS(22例使用T管,58例未放置支架)。未发现与SEABS相关的不良反应。未使用SEABS组的早期胆道并发症(23.8%对2.6%,P<0.001)和住院时间(19天对15天,P = 0.001)更高。未使用SEABS组需要63次内镜逆行胰胆管造影(ERCP)和13次手术(包括2例肝移植),而SEABS组为35次ERCP和2次手术。在对SEABS组(n = 58)和未使用SEABS组(n = 58)进行倾向评分匹配后,未使用SEABS组的早期胆道并发症更高(40%对0%,P<0.001)。与SEABS高风险胆管吻合相比,T管的早期胆道并发症更多(22.7%对5%,P = 0.23)。与T管和未放置支架相比,SEABS每位患者的额外成本更低(分别为6988欧元对17992欧元对36364欧元,P = 0.036和P = 0.002)。
肝移植胆管吻合术中使用SEABS是可行的,无不良反应,并且在高风险胆管吻合中可避免使用T管。其使用与更少的早期胆道并发症、医院成本以及为解决胆道并发症而进行的再次手术或介入治疗相关。